Señales en vivo de AB.PA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 11:35):

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines...

Stats
Volumen de hoy	79 283.00
Volumen promedio	130 285
Capitalización de mercado	98.83M
EPS	€0 ( 2024-04-29 )
Próxima fecha de ganancias	( €0 ) 2024-06-28
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-5.27
ATR14	€0.00600 (0.32%)

Volumen Correlación

Largo: -0.08 (neutral)

Corto: 0.42 (neutral)

Signal:(50.854) Neutral

AB Science SA Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AB Science SA Correlación - Moneda/Commodity

0.32
( neutral )

0.55
( weak )

0.00
( neutral )

0.52
( weak )

-0.71
( moderate negative )

AB Science SA Finanzas

Annual	2022
Ingresos:	€958 000
Beneficio Bruto:	€927 000 (96.76 %)
EPS:	€-0.290

FY	2022
Ingresos:	€958 000
Beneficio Bruto:	€927 000 (96.76 %)
EPS:	€-0.290

FY	2021
Ingresos:	€1.61M
Beneficio Bruto:	€1.50M (93.09 %)
EPS:	€-0.300

FY	2020
Ingresos:	€1.58M
Beneficio Bruto:	€1.51M (95.64 %)
EPS:	€-0.382

Financial Reports:

No articles found.

AB Science SA

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.